Trends

Dealmaking and R&D

Text search

Sort by Name

Click to order products ascending

Display 45 Products per page

Big Pharma Licensing Trends, 2011–15

$5,000.00

Between 2011 and 2015, Big Pharma – a peer set of approximately 16 firms across the world with large R&D and sales organizations, and sales valued at $10bn or more – signed over 1,100 drug-focused deals, growing at a compound annual growth rate of 10%.
October 14, 2016
Find out more
Big Pharma Licensing Trends, 2012–16

$2,995.00

Between 2012 and 2016, Big Pharma – a peer set of approximately 16 firms across the world with large R&D and sales organizations, and annual revenues in excess of $10bn – signed over 1,200 drug-focused deals, growing at a compound annual growth rate of 12%.
March 8, 2017
Find out more
Big Pharma Licensing Trends, 2014–18

$2,995.00

An analysis of the drug-focused licensing deals (out-licensing and in-licensing) made by Big Pharma companies shows an uptick in partnering from 2014 to 2015, followed by a slight decrease in 2016 that has held steady through 2018. Despite that slight decline, the peer set increased deal volume by roughly 15% between the beginning and the end of the five-year period. Total deal values rose even more, roughly 25%.
August 20, 2019
Find out more
Biosimilar Insulin Market Access

$2,995.00

Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants Toujeo and Tresiba. More aggressive payers are excluding branded insulin products in favor of the less expensive biosimilar, forcing switches in existing patient populations. As such, manufacturers of branded insulin products will need to offer deeper discounts to remain on payers’ formularies and contracts.
June 19, 2017
Find out more
Biosimilars Portfolio and Pipeline Trends, 2016

$2,995.00

Biosimilars are expected to drive significant cost savings for healthcare systems, yet there are many considerations that will affect the success of biosimilars, ranging from clinical development, regulatory approval, and ongoing legal disputes around patents. In the US, this is still a seminal period, and for that reason the potential effects of biosimilars in terms of levels of competition are still too early to gauge. Still, European experience with biosimilars may give an indication as to how market dynamics will play out and the degree to which biosimilar sponsors may discount their biosimilars in the US.
November 23, 2016
Find out more
Catch Up On CAR-T

$699.00

Sale!
With the approval of the first CAR-T therapies – Novartis’ Kymriah and Gilead/Kite’s Yescarta – what had been the promise of cutting-edge science is now reality.
November 24, 2017
Find out more
Data in Healthcare: Underpinning the Shift to Value

$2,995.00

Data plays a key role in healthcare systems’ shifts towards value-focused outcomes. Such data includes outcomes and cost data, adherence data, and increasingly, patient-reported data, behavioral and social media data.
November 23, 2016
Find out more
Datamonitor Healthcare Strategy: Immuno-Oncology Deal Trends, 2014–18

$2,995.00

Immuno-oncology continues to draw pharma companies to the deal table.
August 5, 2019
Find out more
From R&D Investment to Externalization: Where is the Pharma Industry Maximizing Value?

$2,995.00

Pharmaceutical companies are attempting to maximize value from all angles, including internal investment in R&D and externalization via deal-making.
June 8, 2017
Find out more
Gene Therapy Pipeline and Portfolio Analysis

$3,000.00

Gene therapy has undergone transformative enhancements over the last 20 years, with improvements to technologies and advances in the pipeline that aim to invigorate the field in its second generation.
April 23, 2019
Find out more
Immuno-Oncology Deal Trends, 2011–15

$5,000.00

Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated. The Big Pharma and Mid Pharma peer sets are an integral part of development and have been furthering efforts via deal-making.
October 14, 2016
Find out more
Immuno-Oncology Deal Trends, 2012–16

$2,995.00

Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated.
April 19, 2017
Find out more
Innovation in Deal-Making

$3,000.00

In order to continually and effectively compete with its peers, as well as with smaller specialty pharmaceutical companies and biotechnology companies, the top 20 global pharmaceutical peer set turns to deal-making as a means to balance out its internally developed portfolio, and to take advantage of the broader capabilities of partners or takeover targets.
June 13, 2018
Find out more
Mid Pharma Outlook

$3,000.00

Total sales from the mid pharma peer set amounted to $69.4bn in 2011; by the end of 2012, this figure rose by 1.6% to $71.0bn. During 2012 the peer set constituents exhibited varying degrees of sales growth.
September 28, 2016
Find out more
New Pharma Models for a New Healthcare Era

$2,995.00

This analysis includes insights from eight interviewed experts from pharma, medical device, or digital health companies.
December 20, 2018
Find out more
PD-1/L1 Immunotherapies: Historical Sales and Market Trend Analysis Report

$7,500.00

Bristol-Myers Squibb’s (BMS) Opdivo (nivolumab) has outpaced Merck’s Keytruda (pembrolizumab) primarily
in non-small cell lung cancer (NSCLC) because of its early approval in squamous NSCLC, updated National
Comprehensive Cancer Network (NCCN) guidelines in 2015,
December 22, 2016
Find out more
Pharma Externalization Strategies 2016: Externalization is Critical to Pharma Revenue

$2,995.00

Pharmaceutical companies constantly re-assess their pipelines and portfolios to determine the best strategies for their business.
October 17, 2016
Find out more
Pharma-Payer Partnerships in Emerging Markets

$2,995.00

Payer partnerships are becoming widespread as emerging markets become wealthier, but access challenges remain. Partnerships with proven success include “strategic philanthropy,” patient access programs, tiered pricing, and service support models.
July 26, 2017
Find out more
Pharma’s Patient Centricity

$2,995.00

Patient centricity is the buzzword of this decade, and necessarily so: it either underpins, or is an inevitable result of, all the forces shaping today’s rapidly evolving healthcare landscape.
October 17, 2016
Find out more
Post-ADPD Alzheimer’s Disease KOL Interview

$599.00

Key Highlights BIIB-037 Amyloid beta PET data show positive Abeta reduction; cognitive results are not interpretable with such small numbers. (BIIB) BIIB-037 Phase Ib result interpretation may be effected by the ApoE4 dropouts in the treatment arm. (BIIB) MK-8931 and BIIB-037 show sufficient target engagement, but there is no evidence to date that amyloid clearance […]
April 8, 2015
Find out more
Precision Medicine and the Future of Healthcare

$2,995.00

Precision medicine is typically associated with the use of therapies that target particular disease-linked genetic mutations, identified via a diagnostic test.
October 14, 2016
Find out more
Product Launch and Commercialization Strategies

$2,995.00

Recent years have seen changes in the marketplace that have made successful new drug launches difficult to achieve. Many therapy areas are becoming hypercompetitive, with similar treatments jostling for position, and even those products with evidence of superior efficacy or better tolerability still have to overcome reimbursement hurdles.
December 12, 2016
Find out more
Profitability Assessment of Branded Generic Inhalers

$2,995.00

We set out to examine the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic and generic inhaled products.
October 31, 2016
Find out more
R&D Trends 2016

$2,995.00

Over the nine-year period from 2006 to 2014, the Big Pharma, Mid Pharma, and Japan Pharma peer sets collectively spent an annual average of $94bn on R&D of pharmaceuticals, with spending growing at a compound annual growth rate (CAGR) of 6%.
October 17, 2016
Find out more
Regenerative Medicine Landscape

$2,995.00

The competitive landscape for regenerative medicine continues to evolve. As private sector investment in active players continues, efforts by governments in the US and EU are helping to advance the field, including the recent passage of the 21st Century Cures Act in the US, providing a special status pathway for regenerative medicine advanced therapies.
July 21, 2017
Find out more
Trends in Gene Therapy

$2,995.00

Datamonitor Healthcare has carried out a comprehensive analysis of gene therapy products in commercial development worldwide based on information derived from Pharmaprojects.
October 14, 2016
Find out more
When Deals Go Wrong: Lessons from Failure

$2,995.00

Acquisitions and licensing are core to pharma and big biotech growth as pipelines thin and assets lose patent protection. Yet a look back at prior years’ eye-popping deal sums reveals many billions of dollars of write-offs and lost value. Key assets failed or disappointed in at least half of 2014’s largest acquisitions and licensing deals. Failure is part of the drug discovery landscape, but some lessons can be learned from dud deals.

July 12, 2019
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *